

Global Relapsing-Remitting Multiple Sclerosis Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/G235594DD7A5EN.html>

Date: February 2023

Pages: 112

Price: US\$ 3,660.00 (Single User License)

ID: G235594DD7A5EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

LPI (LP Information)' newest research report, the "Relapsing-Remitting Multiple Sclerosis Industry Forecast" looks at past sales and reviews total world Relapsing-Remitting Multiple Sclerosis sales in 2022, providing a comprehensive analysis by region and market sector of projected Relapsing-Remitting Multiple Sclerosis sales for 2023 through 2029. With Relapsing-Remitting Multiple Sclerosis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Relapsing-Remitting Multiple Sclerosis industry.

This Insight Report provides a comprehensive analysis of the global Relapsing-Remitting Multiple Sclerosis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Relapsing-Remitting Multiple Sclerosis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Relapsing-Remitting Multiple Sclerosis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Relapsing-Remitting Multiple Sclerosis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Relapsing-Remitting Multiple Sclerosis.

The global Relapsing-Remitting Multiple Sclerosis market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Relapsing-Remitting Multiple Sclerosis is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Relapsing-Remitting Multiple Sclerosis is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Relapsing-Remitting Multiple Sclerosis is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Relapsing-Remitting Multiple Sclerosis players cover Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Merck & Co., Inc, Sanofi, Teva Pharmaceutical Industries and GlaxoSmithKline, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Relapsing-Remitting Multiple Sclerosis market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Oral

Intravenous Injection

Segmentation by application

Hospital

Clinic

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Biogen

Novartis

Roche

Bayer HealthCare

Pfizer

Merck & Co., Inc

Sanofi

Teva Pharmaceutical Industries

GlaxoSmithKline

Acorda Therapeutics

Actelion Pharmaceuticals (Johnson & Johnson)

AbbVie

CinnoVex

Extavia

Tysabr

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Relapsing-Remitting Multiple Sclerosis Market Size 2018-2029
 - 2.1.2 Relapsing-Remitting Multiple Sclerosis Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Relapsing-Remitting Multiple Sclerosis Segment by Type
 - 2.2.1 Oral
 - 2.2.2 Intravenous Injection
- 2.3 Relapsing-Remitting Multiple Sclerosis Market Size by Type
 - 2.3.1 Relapsing-Remitting Multiple Sclerosis Market Size CAGR by Type (2018 VS 2022 VS 2029)
 - 2.3.2 Global Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Type (2018-2023)
- 2.4 Relapsing-Remitting Multiple Sclerosis Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinic
- 2.5 Relapsing-Remitting Multiple Sclerosis Market Size by Application
 - 2.5.1 Relapsing-Remitting Multiple Sclerosis Market Size CAGR by Application (2018 VS 2022 VS 2029)
 - 2.5.2 Global Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Application (2018-2023)

3 RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET SIZE BY PLAYER

- 3.1 Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Players

- 3.1.1 Global Relapsing-Remitting Multiple Sclerosis Revenue by Players (2018-2023)
- 3.1.2 Global Relapsing-Remitting Multiple Sclerosis Revenue Market Share by Players (2018-2023)
- 3.2 Global Relapsing-Remitting Multiple Sclerosis Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
 - 3.3.1 Competition Landscape Analysis
 - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion

4 RELAPSING-REMITTING MULTIPLE SCLEROSIS BY REGIONS

- 4.1 Relapsing-Remitting Multiple Sclerosis Market Size by Regions (2018-2023)
- 4.2 Americas Relapsing-Remitting Multiple Sclerosis Market Size Growth (2018-2023)
- 4.3 APAC Relapsing-Remitting Multiple Sclerosis Market Size Growth (2018-2023)
- 4.4 Europe Relapsing-Remitting Multiple Sclerosis Market Size Growth (2018-2023)
- 4.5 Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size Growth (2018-2023)

5 AMERICAS

- 5.1 Americas Relapsing-Remitting Multiple Sclerosis Market Size by Country (2018-2023)
- 5.2 Americas Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023)
- 5.3 Americas Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Relapsing-Remitting Multiple Sclerosis Market Size by Region (2018-2023)
- 6.2 APAC Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023)
- 6.3 APAC Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023)
- 6.4 China

- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Relapsing-Remitting Multiple Sclerosis by Country (2018-2023)
- 7.2 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023)
- 7.3 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Relapsing-Remitting Multiple Sclerosis by Region (2018-2023)
- 8.2 Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023)
- 8.3 Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL RELAPSING-REMITTING MULTIPLE SCLEROSIS MARKET FORECAST

- 10.1 Global Relapsing-Remitting Multiple Sclerosis Forecast by Regions (2024-2029)
 - 10.1.1 Global Relapsing-Remitting Multiple Sclerosis Forecast by Regions (2024-2029)
 - 10.1.2 Americas Relapsing-Remitting Multiple Sclerosis Forecast
 - 10.1.3 APAC Relapsing-Remitting Multiple Sclerosis Forecast
 - 10.1.4 Europe Relapsing-Remitting Multiple Sclerosis Forecast
 - 10.1.5 Middle East & Africa Relapsing-Remitting Multiple Sclerosis Forecast
- 10.2 Americas Relapsing-Remitting Multiple Sclerosis Forecast by Country (2024-2029)
 - 10.2.1 United States Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.2.2 Canada Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.2.3 Mexico Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.2.4 Brazil Relapsing-Remitting Multiple Sclerosis Market Forecast
- 10.3 APAC Relapsing-Remitting Multiple Sclerosis Forecast by Region (2024-2029)
 - 10.3.1 China Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.3.2 Japan Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.3.3 Korea Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.3.4 Southeast Asia Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.3.5 India Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.3.6 Australia Relapsing-Remitting Multiple Sclerosis Market Forecast
- 10.4 Europe Relapsing-Remitting Multiple Sclerosis Forecast by Country (2024-2029)
 - 10.4.1 Germany Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.4.2 France Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.4.3 UK Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.4.4 Italy Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.4.5 Russia Relapsing-Remitting Multiple Sclerosis Market Forecast
- 10.5 Middle East & Africa Relapsing-Remitting Multiple Sclerosis Forecast by Region (2024-2029)
 - 10.5.1 Egypt Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.5.2 South Africa Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.5.3 Israel Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.5.4 Turkey Relapsing-Remitting Multiple Sclerosis Market Forecast
 - 10.5.5 GCC Countries Relapsing-Remitting Multiple Sclerosis Market Forecast
- 10.6 Global Relapsing-Remitting Multiple Sclerosis Forecast by Type (2024-2029)
- 10.7 Global Relapsing-Remitting Multiple Sclerosis Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 Biogen

- 11.1.1 Biogen Company Information
- 11.1.2 Biogen Relapsing-Remitting Multiple Sclerosis Product Offered
- 11.1.3 Biogen Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)
- 11.1.4 Biogen Main Business Overview
- 11.1.5 Biogen Latest Developments
- 11.2 Novartis
 - 11.2.1 Novartis Company Information
 - 11.2.2 Novartis Relapsing-Remitting Multiple Sclerosis Product Offered
 - 11.2.3 Novartis Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)
 - 11.2.4 Novartis Main Business Overview
 - 11.2.5 Novartis Latest Developments
- 11.3 Roche
 - 11.3.1 Roche Company Information
 - 11.3.2 Roche Relapsing-Remitting Multiple Sclerosis Product Offered
 - 11.3.3 Roche Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)
 - 11.3.4 Roche Main Business Overview
 - 11.3.5 Roche Latest Developments
- 11.4 Bayer HealthCare
 - 11.4.1 Bayer HealthCare Company Information
 - 11.4.2 Bayer HealthCare Relapsing-Remitting Multiple Sclerosis Product Offered
 - 11.4.3 Bayer HealthCare Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)
 - 11.4.4 Bayer HealthCare Main Business Overview
 - 11.4.5 Bayer HealthCare Latest Developments
- 11.5 Pfizer
 - 11.5.1 Pfizer Company Information
 - 11.5.2 Pfizer Relapsing-Remitting Multiple Sclerosis Product Offered
 - 11.5.3 Pfizer Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)
 - 11.5.4 Pfizer Main Business Overview
 - 11.5.5 Pfizer Latest Developments
- 11.6 Merck & Co., Inc
 - 11.6.1 Merck & Co., Inc Company Information
 - 11.6.2 Merck & Co., Inc Relapsing-Remitting Multiple Sclerosis Product Offered
 - 11.6.3 Merck & Co., Inc Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)

- 11.6.4 Merck & Co., Inc Main Business Overview
- 11.6.5 Merck & Co., Inc Latest Developments
- 11.7 Sanofi
 - 11.7.1 Sanofi Company Information
 - 11.7.2 Sanofi Relapsing-Remitting Multiple Sclerosis Product Offered
 - 11.7.3 Sanofi Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)
 - 11.7.4 Sanofi Main Business Overview
 - 11.7.5 Sanofi Latest Developments
- 11.8 Teva Pharmaceutical Industries
 - 11.8.1 Teva Pharmaceutical Industries Company Information
 - 11.8.2 Teva Pharmaceutical Industries Relapsing-Remitting Multiple Sclerosis Product Offered
 - 11.8.3 Teva Pharmaceutical Industries Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)
 - 11.8.4 Teva Pharmaceutical Industries Main Business Overview
 - 11.8.5 Teva Pharmaceutical Industries Latest Developments
- 11.9 GlaxoSmithKline
 - 11.9.1 GlaxoSmithKline Company Information
 - 11.9.2 GlaxoSmithKline Relapsing-Remitting Multiple Sclerosis Product Offered
 - 11.9.3 GlaxoSmithKline Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)
 - 11.9.4 GlaxoSmithKline Main Business Overview
 - 11.9.5 GlaxoSmithKline Latest Developments
- 11.10 Acorda Therapeutics
 - 11.10.1 Acorda Therapeutics Company Information
 - 11.10.2 Acorda Therapeutics Relapsing-Remitting Multiple Sclerosis Product Offered
 - 11.10.3 Acorda Therapeutics Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)
 - 11.10.4 Acorda Therapeutics Main Business Overview
 - 11.10.5 Acorda Therapeutics Latest Developments
- 11.11 Actelion Pharmaceuticals (Johnson & Johnson)
 - 11.11.1 Actelion Pharmaceuticals (Johnson & Johnson) Company Information
 - 11.11.2 Actelion Pharmaceuticals (Johnson & Johnson) Relapsing-Remitting Multiple Sclerosis Product Offered
 - 11.11.3 Actelion Pharmaceuticals (Johnson & Johnson) Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)
 - 11.11.4 Actelion Pharmaceuticals (Johnson & Johnson) Main Business Overview
 - 11.11.5 Actelion Pharmaceuticals (Johnson & Johnson) Latest Developments

11.12 AbbVie

11.12.1 AbbVie Company Information

11.12.2 AbbVie Relapsing-Remitting Multiple Sclerosis Product Offered

11.12.3 AbbVie Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)

11.12.4 AbbVie Main Business Overview

11.12.5 AbbVie Latest Developments

11.13 CinnoVex

11.13.1 CinnoVex Company Information

11.13.2 CinnoVex Relapsing-Remitting Multiple Sclerosis Product Offered

11.13.3 CinnoVex Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)

11.13.4 CinnoVex Main Business Overview

11.13.5 CinnoVex Latest Developments

11.14 Extavia

11.14.1 Extavia Company Information

11.14.2 Extavia Relapsing-Remitting Multiple Sclerosis Product Offered

11.14.3 Extavia Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)

11.14.4 Extavia Main Business Overview

11.14.5 Extavia Latest Developments

11.15 Tysabr

11.15.1 Tysabr Company Information

11.15.2 Tysabr Relapsing-Remitting Multiple Sclerosis Product Offered

11.15.3 Tysabr Relapsing-Remitting Multiple Sclerosis Revenue, Gross Margin and Market Share (2018-2023)

11.15.4 Tysabr Main Business Overview

11.15.5 Tysabr Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Relapsing-Remitting Multiple Sclerosis Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)

Table 2. Major Players of Oral

Table 3. Major Players of Intravenous Injection

Table 4. Relapsing-Remitting Multiple Sclerosis Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)

Table 5. Global Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023) & (\$ Millions)

Table 6. Global Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Type (2018-2023)

Table 7. Relapsing-Remitting Multiple Sclerosis Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)

Table 8. Global Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023) & (\$ Millions)

Table 9. Global Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Application (2018-2023)

Table 10. Global Relapsing-Remitting Multiple Sclerosis Revenue by Players (2018-2023) & (\$ Millions)

Table 11. Global Relapsing-Remitting Multiple Sclerosis Revenue Market Share by Player (2018-2023)

Table 12. Relapsing-Remitting Multiple Sclerosis Key Players Head office and Products Offered

Table 13. Relapsing-Remitting Multiple Sclerosis Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

Table 14. New Products and Potential Entrants

Table 15. Mergers & Acquisitions, Expansion

Table 16. Global Relapsing-Remitting Multiple Sclerosis Market Size by Regions 2018-2023 & (\$ Millions)

Table 17. Global Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Regions (2018-2023)

Table 18. Global Relapsing-Remitting Multiple Sclerosis Revenue by Country/Region (2018-2023) & (\$ millions)

Table 19. Global Relapsing-Remitting Multiple Sclerosis Revenue Market Share by Country/Region (2018-2023)

Table 20. Americas Relapsing-Remitting Multiple Sclerosis Market Size by Country

(2018-2023) & (\$ Millions)

Table 21. Americas Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Country (2018-2023)

Table 22. Americas Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023) & (\$ Millions)

Table 23. Americas Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Type (2018-2023)

Table 24. Americas Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023) & (\$ Millions)

Table 25. Americas Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Application (2018-2023)

Table 26. APAC Relapsing-Remitting Multiple Sclerosis Market Size by Region (2018-2023) & (\$ Millions)

Table 27. APAC Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Region (2018-2023)

Table 28. APAC Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023) & (\$ Millions)

Table 29. APAC Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Type (2018-2023)

Table 30. APAC Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023) & (\$ Millions)

Table 31. APAC Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Application (2018-2023)

Table 32. Europe Relapsing-Remitting Multiple Sclerosis Market Size by Country (2018-2023) & (\$ Millions)

Table 33. Europe Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Country (2018-2023)

Table 34. Europe Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023) & (\$ Millions)

Table 35. Europe Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Type (2018-2023)

Table 36. Europe Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023) & (\$ Millions)

Table 37. Europe Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Application (2018-2023)

Table 38. Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size by Region (2018-2023) & (\$ Millions)

Table 39. Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Region (2018-2023)

Table 40. Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023) & (\$ Millions)

Table 41. Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Type (2018-2023)

Table 42. Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023) & (\$ Millions)

Table 43. Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Application (2018-2023)

Table 44. Key Market Drivers & Growth Opportunities of Relapsing-Remitting Multiple Sclerosis

Table 45. Key Market Challenges & Risks of Relapsing-Remitting Multiple Sclerosis

Table 46. Key Industry Trends of Relapsing-Remitting Multiple Sclerosis

Table 47. Global Relapsing-Remitting Multiple Sclerosis Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 48. Global Relapsing-Remitting Multiple Sclerosis Market Size Market Share Forecast by Regions (2024-2029)

Table 49. Global Relapsing-Remitting Multiple Sclerosis Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 50. Global Relapsing-Remitting Multiple Sclerosis Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 51. Biogen Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 52. Biogen Relapsing-Remitting Multiple Sclerosis Product Offered

Table 53. Biogen Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 54. Biogen Main Business

Table 55. Biogen Latest Developments

Table 56. Novartis Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 57. Novartis Relapsing-Remitting Multiple Sclerosis Product Offered

Table 58. Novartis Main Business

Table 59. Novartis Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 60. Novartis Latest Developments

Table 61. Roche Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 62. Roche Relapsing-Remitting Multiple Sclerosis Product Offered

Table 63. Roche Main Business

Table 64. Roche Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross

Margin and Market Share (2018-2023)

Table 65. Roche Latest Developments

Table 66. Bayer HealthCare Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 67. Bayer HealthCare Relapsing-Remitting Multiple Sclerosis Product Offered

Table 68. Bayer HealthCare Main Business

Table 69. Bayer HealthCare Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 70. Bayer HealthCare Latest Developments

Table 71. Pfizer Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 72. Pfizer Relapsing-Remitting Multiple Sclerosis Product Offered

Table 73. Pfizer Main Business

Table 74. Pfizer Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 75. Pfizer Latest Developments

Table 76. Merck & Co., Inc Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 77. Merck & Co., Inc Relapsing-Remitting Multiple Sclerosis Product Offered

Table 78. Merck & Co., Inc Main Business

Table 79. Merck & Co., Inc Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 80. Merck & Co., Inc Latest Developments

Table 81. Sanofi Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 82. Sanofi Relapsing-Remitting Multiple Sclerosis Product Offered

Table 83. Sanofi Main Business

Table 84. Sanofi Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 85. Sanofi Latest Developments

Table 86. Teva Pharmaceutical Industries Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 87. Teva Pharmaceutical Industries Relapsing-Remitting Multiple Sclerosis Product Offered

Table 88. Teva Pharmaceutical Industries Main Business

Table 89. Teva Pharmaceutical Industries Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 90. Teva Pharmaceutical Industries Latest Developments

Table 91. GlaxoSmithKline Details, Company Type, Relapsing-Remitting Multiple

Sclerosis Area Served and Its Competitors

Table 92. GlaxoSmithKline Relapsing-Remitting Multiple Sclerosis Product Offered

Table 93. GlaxoSmithKline Main Business

Table 94. GlaxoSmithKline Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 95. GlaxoSmithKline Latest Developments

Table 96. Acorda Therapeutics Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 97. Acorda Therapeutics Relapsing-Remitting Multiple Sclerosis Product Offered

Table 98. Acorda Therapeutics Main Business

Table 99. Acorda Therapeutics Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 100. Acorda Therapeutics Latest Developments

Table 101. Actelion Pharmaceuticals (Johnson & Johnson) Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 102. Actelion Pharmaceuticals (Johnson & Johnson) Relapsing-Remitting Multiple Sclerosis Product Offered

Table 103. Actelion Pharmaceuticals (Johnson & Johnson) Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 104. Actelion Pharmaceuticals (Johnson & Johnson) Main Business

Table 105. Actelion Pharmaceuticals (Johnson & Johnson) Latest Developments

Table 106. AbbVie Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 107. AbbVie Relapsing-Remitting Multiple Sclerosis Product Offered

Table 108. AbbVie Main Business

Table 109. AbbVie Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 110. AbbVie Latest Developments

Table 111. CinnoVex Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 112. CinnoVex Relapsing-Remitting Multiple Sclerosis Product Offered

Table 113. CinnoVex Main Business

Table 114. CinnoVex Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 115. CinnoVex Latest Developments

Table 116. Extavia Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 117. Extavia Relapsing-Remitting Multiple Sclerosis Product Offered

Table 118. Extavia Main Business

Table 119. Extavia Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 120. Extavia Latest Developments

Table 121. Tysabr Details, Company Type, Relapsing-Remitting Multiple Sclerosis Area Served and Its Competitors

Table 122. Tysabr Relapsing-Remitting Multiple Sclerosis Product Offered

Table 123. Tysabr Main Business

Table 124. Tysabr Relapsing-Remitting Multiple Sclerosis Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 125. Tysabr Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Relapsing-Remitting Multiple Sclerosis Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Relapsing-Remitting Multiple Sclerosis Market Size Growth Rate 2018-2029 (\$ Millions)
- Figure 6. Relapsing-Remitting Multiple Sclerosis Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Figure 7. Relapsing-Remitting Multiple Sclerosis Sales Market Share by Country/Region (2022)
- Figure 8. Relapsing-Remitting Multiple Sclerosis Sales Market Share by Country/Region (2018, 2022 & 2029)
- Figure 9. Global Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Type in 2022
- Figure 10. Relapsing-Remitting Multiple Sclerosis in Hospital
- Figure 11. Global Relapsing-Remitting Multiple Sclerosis Market: Hospital (2018-2023) & (\$ Millions)
- Figure 12. Relapsing-Remitting Multiple Sclerosis in Clinic
- Figure 13. Global Relapsing-Remitting Multiple Sclerosis Market: Clinic (2018-2023) & (\$ Millions)
- Figure 14. Global Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Application in 2022
- Figure 15. Global Relapsing-Remitting Multiple Sclerosis Revenue Market Share by Player in 2022
- Figure 16. Global Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Regions (2018-2023)
- Figure 17. Americas Relapsing-Remitting Multiple Sclerosis Market Size 2018-2023 (\$ Millions)
- Figure 18. APAC Relapsing-Remitting Multiple Sclerosis Market Size 2018-2023 (\$ Millions)
- Figure 19. Europe Relapsing-Remitting Multiple Sclerosis Market Size 2018-2023 (\$ Millions)
- Figure 20. Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size 2018-2023 (\$ Millions)
- Figure 21. Americas Relapsing-Remitting Multiple Sclerosis Value Market Share by

Country in 2022

Figure 22. United States Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 23. Canada Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 24. Mexico Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 25. Brazil Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 26. APAC Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Region in 2022

Figure 27. APAC Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Type in 2022

Figure 28. APAC Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Application in 2022

Figure 29. China Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 30. Japan Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 31. Korea Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 32. Southeast Asia Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 33. India Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Australia Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 35. Europe Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Country in 2022

Figure 36. Europe Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Type (2018-2023)

Figure 37. Europe Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Application (2018-2023)

Figure 38. Germany Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 39. France Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 40. UK Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 41. Italy Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 42. Russia Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 43. Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Region (2018-2023)

Figure 44. Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Type (2018-2023)

Figure 45. Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size Market Share by Application (2018-2023)

Figure 46. Egypt Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 47. South Africa Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 48. Israel Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 49. Turkey Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 50. GCC Country Relapsing-Remitting Multiple Sclerosis Market Size Growth 2018-2023 (\$ Millions)

Figure 51. Americas Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 52. APAC Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 53. Europe Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 54. Middle East & Africa Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 55. United States Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 56. Canada Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 57. Mexico Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 58. Brazil Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 59. China Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 60. Japan Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$

Millions)

Figure 61. Korea Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 62. Southeast Asia Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 63. India Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 64. Australia Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 65. Germany Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 66. France Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 67. UK Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 68. Italy Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 69. Russia Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 70. Spain Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 71. Egypt Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 72. South Africa Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 73. Israel Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 74. Turkey Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 75. GCC Countries Relapsing-Remitting Multiple Sclerosis Market Size 2024-2029 (\$ Millions)

Figure 76. Global Relapsing-Remitting Multiple Sclerosis Market Size Market Share Forecast by Type (2024-2029)

Figure 77. Global Relapsing-Remitting Multiple Sclerosis Market Size Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Relapsing-Remitting Multiple Sclerosis Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/G235594DD7A5EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G235594DD7A5EN.html>